Kelly Lohmann, PA
Surgical · Woodbridge, VANPI 1417275629
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,525 of the $88,120 with a category attached, or 80.0%. 15 manufacturers reported payments, led by AbbVie at 51.4% of the total. 2025 is the largest year on record at $31,199, 3.5 times the $8,907 reported in 2021. Among surgical clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 455 payments — averaging $193.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$45K
- Alkermes, Inc.$38K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$639
- Teva Pharmaceuticals USA, Inc.$538
- Johnson & Johnson$474
- plus $2K from 9 others
What the payments were for
- Consulting fees$3,8204%
- Speaking & faculty fees$70,52580%
- Travel & lodging$5,3766%
- Food & beverage$8,1009%
- Education$2980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 181 | $45,338 |
| Alkermes, Inc. | 110 | $38,350 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $1,045 |
| Otsuka America Pharmaceutical, Inc. | 32 | $639 |
| Teva Pharmaceuticals USA, Inc. | 16 | $538 |
| Johnson & Johnson | 15 | $474 |
| Vanda Pharmaceuticals Inc. | 14 | $469 |
| Neurocrine Biosciences, Inc. | 17 | $463 |
| Lundbeck LLC | 13 | $235 |
| E.r. Squibb & Sons, L.L.C. | 10 | $211 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Axsome Therapeutics, Inc. | 4 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $75 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 |
| Indivior Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$145,018
- VRAYLAR$41,337
- ARISTADA$1,013
- CAPLYTA$237
- INVEGA SUSTENNA$226
- Fanapt$218
- ABILIFY MAINTENA$118
- ABILIFY ASIMTUFII$118
How this compares
$88,120 in reported general payments places this provider in the 95th percentile of 201 surgical providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 24 | $216,742 |
| AristadaAripiprazole Lauroxil | 60 | $184,057 |
| Invega SustennaPaliperidone Palmitate | 45 | $145,634 |
| Abilify MaintenaAripiprazole | 43 | $122,450 |
| LybalviOlanzapine/Samidorphan Malate | 63 | $100,117 |
| VraylarCariprazine Hcl | 53 | $87,745 |
| RexultiBrexpiprazole | 47 | $74,177 |
| Risperdal ConstaRisperidone Microspheres | 26 | $39,301 |
| Aripiprazole | 276 | $33,759 |
| CaplytaLumateperone Tosylate | 15 | $26,804 |
| Lurasidone Hcl | 102 | $18,031 |
| FanaptIloperidone | 12 | $17,754 |
| Clomipramine Hcl | 13 | $10,975 |
| Hydroxyzine Hcl | 326 | $8,907 |
| Olanzapine | 219 | $8,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta | $474 | $401,67795 claims |
| Alkermes, Inc.Aristada, Lybalvi | $38,350 | $284,174123 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $639 | $196,62790 claims |
| AbbVieVraylar | $45,338 | $87,74553 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,045 | $26,80415 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $469 | $17,75412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 201 surgical providers in Virginia.
Other surgical in Woodbridge
- Jeanine GargiuloAlexandria$298K
- Alan FitchRichmond$66K
- Kristin LuptonFairfax$16K
- Tyler KempRoanoke$13K
- Rebecca LehmanCharlottesville$11K
- Savannah WrightRoanoke$10K
- Kathryn RobertsonCharlottesville$8K
- Juliana BuendiaReston$7K
- Taylor FrickeCharlottesville$6K
- Taylor RickenbakerVirginia Beach$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.